60 Degrees Pharmaceuticals (SXTP) : 18-month performance

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. 

• Sector:  Healthcare
• Industry: Biotechnology
• Full Time Employees:  3
• founded in 2010 
• Headquartered in Washington, District Of Columbia
• https://www.60degreespharma.com

IPO: Fri 14 July 2023

60 Degrees Pharmaceuticals (NASDAQ: SXTP) focuses on developing and commercializing medicines for infectious and vector-borne diseases. Their lead drug is ARAKODA® (tafenoquine), an FDA-approved oral medication (approved in 2018) for malaria prevention in adults, marketed in the US and Australia. It's a once-weekly regimen and their primary commercial product.The company's pipeline centers on repurposing tafenoquine for new indications, particularly babesiosis (a tick-borne parasitic infection), alongside earlier-stage efforts in other areas.